


SUPPLEMENTAL DIGITAL CONTENT 5

Snapshot analysis of the proportion of participants with HIV-1 RNA <50 copies/mL by subgroup in the ITT-E population at Week 96, with unadjusted treatment group differences (95% CI).



2DR, 2-drug regimen (dolutegravir + lamivudine); 3DR, 3-drug regimen (dolutegravir + tenofovir disoproxil fumarate/emtricitabine); HCV, hepatitis C virus; ITT-E, intention-to-treat–exposed.